Evidence map›Paper›PMID 20533872›Full record

ArticleThe Journal of infectious diseases2010

Possible mitochondrial dysfunction and its association with antiretroviral therapy use in children perinatally infected with HIV.

Marilyn J Crain, Miriam C Chernoff, James M Oleske, Susan B Brogly, Kathleen M Malee, Peggy R Borum, William A Meyer, Wendy G Mitchell, John H Moye, Heather M Ford-Chatterton and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Review
  6. Article
  7. Article
  8. Hearing loss among HIV-seropositive and HIV-seronegative men and women.JAMA otolaryngology-- head & neck surgery · 2015
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 11 institutions in 2 countries.

Marilyn J CrainUniversity of Alabama School of Medicine, Birmingham, AL 35233, USA. mcrain@peds.uab.edu
Miriam C Chernoff
James M Oleske
Susan B Brogly
Kathleen M Malee
Peggy R Borum
William A Meyer
Wendy G Mitchell
John H Moye
Heather M Ford-Chatterton
Russell B Van Dyke
George R Seage Iii
Cancer Research And Biostatistics · USEunice Kennedy Shriver National Institute of Child Health and Human Development · USFrontier Science & Technology Research Foundation · USHarvard University · USLurie Children's Hospital · USQuest Diagnostics (United Kingdom) · GBTulane University · USUniversity Hospital, Newark · USUniversity of Alabama at Birmingham · USUniversity of Florida · USUniversity of Southern California · US

Funding

LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Jennifer Jao, Sharon A Nachman · 2011 to 2026
$278.1M
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) GroupU01AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI JACKSON, J BROOKS · 2006 to 2010
$109.7M
Statistical/Data Management Center-Pediatric AIDS CTGU01AI041110 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI FENTON, TERRENCE · 1997 to 2006
$38.6M
Statistical and Data Management Center-Pediatric,Adolescent, and Maternal CTGU01AI068616 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI SHAPIRO, DAVID ERIC · 2006 to 2010
$38.6M
ZENARESTAT IN DIABETIC NEUROPATHYM01RR005096 · NCRR · TULANE UNIVERSITY OF LOUISIANA · PI FONSECA, VIVIAN A · 1990 to 2006
$17.4M
NCRR NIH HHS M01 RR005096NCRR NIH HHS RR05096NIAID NIH HHS 1 U01 AI068616NIAID NIH HHS 5 U01 AI41110NIAID NIH HHS AI068632NIAID NIH HHS U01 AI041110NIAID NIH HHS U01 AI068616NIAID NIH HHS U01 AI068632NICHD NIH HHS HHSN267200800001CNIDDK NIH HHS HHSN267200800001GPHS HHS N01-3-3345
6 · The paper itself

Abstract

backgroundMitochondrial dysfunction has been associated with both human immunodeficiency virus (HIV) infection and exposure to antiretroviral therapy. Mitochondrial dysfunction has not been widely studied in HIV-infected children. We estimated the incidence of clinically defined mitochondrial dysfunction among children with perinatal HIV infection.

methodsChildren with perinatal HIV infection enrolled in a prospective cohort study (Pediatric AIDS Clinical Trials Group protocols 219 and 219C) from 1993 through 2004 were included. Two clinical case definitions of mitochondrial dysfunction, the Enquête Périnatale Française criteria and the Mitochondrial Disease Classification criteria, were used to classify signs and symptoms that were consistent with possible mitochondrial dysfunction. Adjusted odds ratios of the associations between single and dual nucleoside reverse-transcriptase inhibitor use and possible mitochondrial dysfunction were estimated using logistic regression.

resultsOverall, 982 (33.5%) of 2931 children met 1 or both case definitions of possible mitochondrial dysfunction. Mortality was highest among the 96 children who met both case definitions (20%). After adjusting for confounders, there was a higher risk of possible mitochondrial dysfunction among children who received stavudine regardless of exposure to other medications (odds ratio, 3.44 [95% confidence interval, 1.91-6.20]) or who received stavudine-didanosine combination therapy (odds ratio, 2.23 [95% confidence interval, 1.19-4.21]). Exposure to lamivudine and to lamivudine-stavudine were also associated with an increased risk of mitochondrial dysfunction.

conclusionsReceipt of nucleoside reverse-transcriptase inhibitors, especially stavudine and lamivudine, was associated with possible mitochondrial dysfunction in children with perinatal HIV infection. Further studies are warranted to elucidate potential mechanisms of nucleoside reverse-transcriptase inhibitor toxicities.

Indexed as

AdolescentAnti-HIV AgentsChildChild, PreschoolCohort StudiesFemaleHIV InfectionsHumansInfant, NewbornMaleMitochondrial DiseasesPregnancyPrenatal Exposure Delayed EffectsProspective StudiesRegression AnalysisStavudineAnti-HIV AgentsStavudineZidovudine

Identifiers

PMID20533872
PMCPMC2913975
OpenAlexW2136910488

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.